iRhythm’s Kevin King Set to Retire from Board

King was once the San Francisco-based company’s president and CEO. He had served on the company’s board since July 2012.

Omar Ford

March 14, 2022

1 Min Read
Image courtesy of ZUMA Press Inc / Alamy Stock Photo

It’s the end of an era for iRhythm Technologies as Kevin King is set to retire from the company’s board in April.

King joined the wearable heart monitor specialist’s board in July of 2012 and served as the San Francisco-based company’s president and CEO from July 2012 to January 2021. Mike Coyle took on the role as president and CEO after King but resigned in June of 2021 citing personal matters.

Ultimately, Quentin Blackford, who once served as Dexcom’s COO, stepped in to fill the president and CEO role in October of 2021.  

“On behalf of the entire iRhythm team, I would like to thank Kevin for his contributions over the last several years,” Blackford said in prepared remarks. “iRhythm would not be the company that it is today without Kevin’s leadership and we thank him for the many achievements during his tenure.”

Under King’s leadership, iRhythm was transformed in many ways. He helped put the Zio Patch, a wearable ECG, out front and center. He also shepherded the company through the process of going public in 2016 and raised $107 million in an IPO.

During his tenure, the company formed a strategic collaboration with Alphabet’s Verily Life Sciences. The two organizations noted the collaboration would help improve the atrial fibrillation patients.

“In my 10 years with the company, iRhythm has grown into a market-leading company that has changed the standard of care in cardiac monitoring,” King said in a release. “We have served over four million patients and I am extremely proud of all that we have accomplished. It has been an amazing journey and I am looking forward to watching the company’s continued success under Quentin’s leadership.”


About the Author(s)

Omar Ford

Omar Ford is MD+DI's Editor-in-Chief. You can reach him at [email protected].


Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like